Ownership Capital B.V. Lowers Position in Illumina, Inc. (NASDAQ:ILMN)

Ownership Capital B.V. lessened its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 6.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 791,187 shares of the life sciences company's stock after selling 58,462 shares during the quarter. Illumina accounts for approximately 3.9% of Ownership Capital B.V.'s investment portfolio, making the stock its 14th biggest position. Ownership Capital B.V. owned about 0.50% of Illumina worth $105,726,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Versant Capital Management Inc boosted its holdings in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after purchasing an additional 146 shares in the last quarter. Golden State Wealth Management LLC acquired a new stake in shares of Illumina during the 4th quarter valued at $32,000. TD Private Client Wealth LLC boosted its holdings in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock valued at $50,000 after acquiring an additional 141 shares in the last quarter. V Square Quantitative Management LLC boosted its holdings in shares of Illumina by 50.6% during the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company's stock valued at $52,000 after acquiring an additional 132 shares in the last quarter. Finally, Private Trust Co. NA boosted its holdings in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company's stock valued at $62,000 after acquiring an additional 212 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Wall Street Analysts Forecast Growth

ILMN has been the topic of several recent research reports. Royal Bank of Canada cut their target price on Illumina from $250.00 to $247.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. JPMorgan Chase & Co. lifted their target price on Illumina from $125.00 to $140.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. UBS Group lifted their target price on Illumina from $133.00 to $145.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. Guggenheim cut their target price on Illumina from $170.00 to $150.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Finally, Canaccord Genuity Group cut their target price on Illumina from $145.00 to $135.00 and set a "hold" rating on the stock in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $159.45.

Illumina Stock Down 3.1 %

Shares of Illumina stock traded down $3.00 on Friday, hitting $94.20. The company had a trading volume of 4,225,715 shares, compared to its average volume of 2,592,243. The stock has a market capitalization of $14.92 billion, a price-to-earnings ratio of -12.27, a P/E/G ratio of 1.70 and a beta of 1.10. Illumina, Inc. has a 1 year low of $93.50 and a 1 year high of $156.66. The stock has a 50 day moving average of $128.97 and a 200-day moving average of $134.16. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, sell-side analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.